-
Benzinga’s Biggest Losers (BZ, ADSK, ILMN, CRM, NANO, ONCY)
Wednesday, November 18, 2009 - 11:51am | 325Boise Inc. (NYSE: BZ) fell 5% to $4.85 huge volume of 8.37 million shares after Boise Inc. announced that the previously announced secondary offering of 17 million shares of its common stock has been priced at $4.85 per share. Pursuant to the offering, all of the shares will be sold by the selling...
-
Benzinga’s Top Pre- Market Losers (ADSK, CNQR, TEN, EMS, DRYS, CRM, EXEL)
Wednesday, November 18, 2009 - 9:35am | 321Autodesk, Inc. (NASDAQ: ADSK) fell 8% to $24.85 in the pre-market session. Yesterday, it reported Q3 EPS of $0.27; these are 4 cents better than the analyst estimate of $0.23. Revenue for the quarter was $417 million Vs $415.33 million consensus. Autodesk sees Q4 EPS of $0.19-$0.24 Vs consensus of...
-
GENZ's Lumizyme Approval Delayed - Analyst Blog
Tuesday, November 17, 2009 - 4:56pm | 378Genzyme Corporation’s (GENZ) Lumizyme failed to receive approval from the US Food and Drug Administration (FDA) for the treatment of Pompe disease. The FDA issued a complete response letter (CRL) stating that the agency will not grant approval unless the company addresses the manufacturing issues...
-
Uncertainty in the Start of the GLP Toxicology Services Led to a Downgrade of WuXi PharmaTech
Monday, November 16, 2009 - 1:31pm | 132Credit Suisse has downgraded its rating for WuXi PharmaTech Cayman Inc (NYSE: WX) to "neutral." The target price has been raised from $12 to $14. According to Credit Suisse, Q3 results of Charles River and Covance have indicated how substantial pricing pressure has been caused by excess capacity...
-
Benzinga’s Top 5 Gainers (MPAC, NILE, HLCS, ASEI, CRIC)
Monday, November 9, 2009 - 9:36am | 215MOD-PAC Corp (NASDAQ: MPAC) shares have risen by 7.82% in the pre-market trading. MPAC reported its strongest quarterly profits in nearly four years, with profits rising to $1 million, or $0.29 per share, from $14,000, or less than a penny per share, a year earlier. Blue Nile Inc (NASDAQ: NILE)...
-
Medivation upgraded to Buy at Roth Capital
Thursday, November 5, 2009 - 9:22am | 57Roth Capital upgraded Medivation (NASDAQ: MDVN) from “hold” to “buy.” The upgrade was based on a 65% probability of the FDA approving Medivation's Alzheimer treatment, Dimebon. Roth Capital has set the target price for MDVN at $34 and has recommended purchase of MDVN shares before the company...
-
China Stocks Up For The Fourth Straight Day (WX, YZC, BIDU, SOHU)
Wednesday, November 4, 2009 - 3:01pm | 235China stocks show a great deal of potential as futures for their market continues to go up. The increasing prices of stocks point toward a momentum that should keep moving positively. On November 4 the stocks rose for the fourth straight day making this the longest winning streak since September 9...
-
JP Morgan Starts Coverage on Medivation With A Buy, And A $45 Price Target
Thursday, October 29, 2009 - 8:00am | 37JPMorgan starts coverage of Medivation (Nasdaq: MDVN) with a Buy rating and a $45 price target. Medivation is trading at $25 today, JPMorgan's price target represents an 80% premium to where MDVN is trading now.
-
After-Hours Top Losers (FSLR, HLIT, PODD, AFFX)
Wednesday, October 28, 2009 - 6:50pm | 107First Solar (NASDAQ: FSLR) dropped 14.90% in the after-hours as its 3Q sales failed to beat analysts' expectation. Its last trade was recorded at $129. Harmonic Inc. (NASDAQ: HLIT) reported 73% drop in earnings which resulted in an after-hours sell off. HLIT dropped 14.14% and its last sale was...
-
Benzinga’s Top Upgrades (WAT, PMTC, DWA, INCY)
Wednesday, October 28, 2009 - 10:34am | 89Waters Corporation (NYSE: WAT) moved up 2.33% to $58.52 after multiple upgrades from Leerink Swann and Deutsche Securities. Parametric Technology (NASDAQ: PMTC) also rallied 4.21% to $15.84 after Needham upgrades PMTC to Buy from Hold with a price target of $19. DreamWorks Animation SKG, Inc. (...
-
Pre-Market Losers (APOL, SAP, ILMN, SPW, FISV)
Wednesday, October 28, 2009 - 9:36am | 113Apollo Group (Nasdaq: APOL) is trading down 15% to $61.85. Apollo is trading down after reporting disappointing results and after APOL announced a SEC investigation. SAP AG (NYSE: SAP) is down 7.75% to $47.21 after lackluster earnings and revenue. Illumina (Nasdaq: ILMN) down 17% to $34.50 after...
-
Earnings Round Up (WSII, APOL, ELMN, QTM, AMKR, ETFC)
Wednesday, October 28, 2009 - 5:58am | 236Waste Services Inc. (NASDAQ: WSII) reports Q3 EPS of $0.15, 4 cents better than the analyst estimate of $0.11. Revenue for the quarter was $112.46 million, which compares to the estimate of $112.10 million. Apollo Group (NASDAQ: APOL) reports Q4 EPS of $1.02, 2 cents better than the analyst...
-
Astellas and Medivation Enter Into Worldwide Agreement (MDVN), Medivation To Receive $110M Up-Front
Tuesday, October 27, 2009 - 7:41am | 128Astellas Pharma Inc. and Medivation, Inc. (Nasdaq: MDVN) announced that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial...
-
Sequenom (SQNM) Announces Paul Maier to Become Interim Chief Financial Officer
Monday, October 26, 2009 - 4:22pm | 46Sequenom, Inc. (Nasdaq: SQNM) announced that Paul V. Maier has been appointed as the company's interim chief financial officer effective November 10, 2009, reporting directly to the company's interim chief executive officer and chairman of the board, Harry F. Hixson, Jr., Ph.D.
-
Somaxon Pharmaceuticals (SOMX) to Present at 8th Annual BIO Investor Forum
Thursday, October 22, 2009 - 9:13am | 95Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) announced that Richard W. Pascoe, Somaxon’s president and chief executive officer, will be presenting at the 2009 BIO Investor Forum on October 28 at 3:00 P.M. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 8th Annual BIO...